{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T23:17:36Z","timestamp":1783120656087,"version":"3.54.6"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:00:00Z","timestamp":1778889600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010663","name":"H2020 European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008433","name":"Community of Madrid Department of Education Science and Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008433","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"State Agency of Research","doi-asserted-by":"publisher","award":["PID2022-136307OBC21"],"award-info":[{"award-number":["PID2022-136307OBC21"]}],"id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"State Agency of Research","doi-asserted-by":"publisher","award":["SAF 2012-40075-C02\\u201301"],"award-info":[{"award-number":["SAF 2012-40075-C02\\u201301"]}],"id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004895","name":"European Social Fund Plus","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003339","name":"Consejo Superior de Investigaciones Cient\u00edficas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018491","name":"Health Sciences, University of Arizona","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012818","name":"Comunidad de Madrid","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.intimp.2026.116884","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T12:07:03Z","timestamp":1779192423000},"page":"116884","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["TLR4 receptor blockade diminishes cardiac and renal toxicity induced by cisplatin treatment in rats"],"prefix":"10.1016","volume":"183","author":[{"given":"Antonio","family":"Gonz\u00e1lez-Ruiz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Flaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor","family":"Fern\u00e1ndez-Cabello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Quesada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Visitaci\u00f3n","family":"L\u00f3pez-Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esperanza","family":"Herrad\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2026.116884_bb0005","first-page":"309","article-title":"Cardiotoxicity of anticancer treatments: epidemiology, detection, and management","volume":"66","author":"Curigliano","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.intimp.2026.116884_bb0010","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jacc.2022.04.042","article-title":"Cardiovascular disease risk among cancer survivors: the ARIC study","volume":"80","author":"Florido","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.intimp.2026.116884_bb0015","doi-asserted-by":"crossref","first-page":"14545","DOI":"10.1002\/cam4.5980","article-title":"Current perspectives of cardio-oncology: epidemiology, adverse effects, pre-treatment screening and prevention strategies","volume":"12","author":"Bychowski","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.intimp.2026.116884_bb0020","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.intimp.2026.116884_bb0025","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","article-title":"Cisplatin in cancer therapy: molecular mechanisms of action","volume":"740","author":"Dasari","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.intimp.2026.116884_bb0030","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s12026-022-09307-7","article-title":"Role of inflammation and oxidative stress in chemotherapy-induced neurotoxicity","volume":"70","author":"Gupta","year":"2022","journal-title":"Immunol. Res."},{"key":"10.1016\/j.intimp.2026.116884_bb0035","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/1462802","article-title":"Cisplatin-induced rodent model of kidney injury: characteristics and challenges","author":"Per\u0161e","year":"2018","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.intimp.2026.116884_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107511","article-title":"Targeting the NLRP3 inflammasome to treat cardiovascular fibrosis","author":"Pinar","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2026.116884_bb0045","first-page":"519","article-title":"TLR2 and TLR4 antagonism mitigates cerebral small vessel disease","volume":"40","author":"Wang","year":"2024","journal-title":"Biotechnol. Genet. Eng. Rev."},{"key":"10.1016\/j.intimp.2026.116884_bb0050","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1124\/molpharm.122.000595","article-title":"Cisplatin toxicity mediated by TLR4 binding","volume":"103","author":"Domingo","year":"2023","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.intimp.2026.116884_bb0055","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.pharmthera.2015.12.005","article-title":"Toll-like receptors mediating vascular malfunction","volume":"158","author":"Wang","year":"2016","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2026.116884_bb0060","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3389\/fphar.2017.00196","article-title":"Characterization of cardiovascular alterations induced by chronic cisplatin treatments","volume":"8","author":"Herrad\u00f3n","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2026.116884_bb0065","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.1108","article-title":"Cisplatin cycles sustain cardiovascular and renal damage involving TLR4 and NLRP3","author":"Gonz\u00e1lez","year":"2023","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.intimp.2026.116884_bb0070","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11095-019-2745-x","article-title":"Intraperitoneal route of drug administration in experimental studies","volume":"37","author":"Al Shoyaib","year":"2019","journal-title":"Pharm. Res."},{"key":"10.1016\/j.intimp.2026.116884_bb0075","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1211\/0022357011777828","article-title":"Pharmacokinetics of intraperitoneal cisplatin","volume":"53","author":"Tamura","year":"2001","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.intimp.2026.116884_bb0080","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s41684-024-01504-1","article-title":"Murine models of repeated low-dose cisplatin-induced CKD","volume":"54","author":"Su","year":"2025","journal-title":"Lab. Anim"},{"key":"10.1016\/j.intimp.2026.116884_bb0085","article-title":"TLR4\/CD14 blockade in pain models","volume":"150","author":"Garc\u00eda","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.intimp.2026.116884_bb0090","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.2147\/JPR.S317877","article-title":"TLR4 antagonism in experimental osteoarthritis","volume":"14","author":"Ferreira-Gomes","year":"2021","journal-title":"J. Pain Res."},{"key":"10.1016\/j.intimp.2026.116884_bb0095","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.bbrc.2018.06.020","article-title":"Renoprotective effects of TAK-242","volume":"503","author":"Mohammad","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.intimp.2026.116884_bb0100","article-title":"TLR4 and AT1R in hypertension","author":"Mowry","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.intimp.2026.116884_bb0105","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1042\/CS20110523","article-title":"TLR4 in blood pressure regulation","volume":"122","author":"Bomfim","year":"2012","journal-title":"Clin. Sci."},{"key":"10.1016\/j.intimp.2026.116884_bb0110","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/cvr\/cvu067","article-title":"Central TLR4 blockade in hypertension","volume":"103","author":"Dange","year":"2014","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.intimp.2026.116884_bb0115","doi-asserted-by":"crossref","first-page":"655","DOI":"10.3389\/fphys.2019.00655","article-title":"TLR4 and blood pressure","volume":"10","author":"Nunes","year":"2019","journal-title":"Front. Physiol."},{"key":"10.1016\/j.intimp.2026.116884_bb0120","article-title":"Cannabinoid-induced delayed gastric emptying","volume":"23","author":"Abalo","year":"2011","journal-title":"Neurogastroenterol. Motil."},{"key":"10.1016\/j.intimp.2026.116884_bb0125","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/dmrr.1176","article-title":"Cannabinoid\/agonist WIN 55,212-2 reduces cardiac ischaemia\u2013reperfusion injury in Zucker diabetic fatty rats: role of CB2 receptors and iNOS\/eNOS","volume":"27","author":"Gonz\u00e1lez","year":"2011","journal-title":"Diabetes Metab. Res. Rev."},{"key":"10.1016\/j.intimp.2026.116884_bb0130","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1590\/S0066-782X2007000200015","article-title":"LV remodeling transition to HF","volume":"88","author":"Bregagnollo","year":"2007","journal-title":"Arq. Bras. Cardiol."},{"key":"10.1016\/j.intimp.2026.116884_bb0135","article-title":"TLR4 and vasopressor response after shock","volume":"3","author":"Mazor","year":"2021","journal-title":"Crit. Care Explor."},{"key":"10.1016\/j.intimp.2026.116884_bb0140","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/978-1-62703-239-1_19","article-title":"Assays for lipid peroxidation","volume":"965","author":"Gasparovic","year":"2013","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.intimp.2026.116884_bb0145","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.692970","article-title":"Vincristine-induced cardiovascular toxicity","volume":"12","author":"Herrad\u00f3n","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2026.116884_bb0150","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1111\/j.1476-5381.2012.01942.x","article-title":"Pharmacology of S1RA","volume":"166","author":"Romero","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.intimp.2026.116884_bb0155","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1021\/jm801333m","article-title":"Glycolipids and benzylammonium lipids as novel antisepsis agents: synthesis and biological characterization","volume":"52","author":"Piazza","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.intimp.2026.116884_bb0160","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1016\/j.bcp.2010.06.019","article-title":"Cationic amphiphiles inhibiting LPS signaling","volume":"80","author":"Piazza","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.intimp.2026.116884_bb0165","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.1021\/jm401006s","article-title":"TLR4 modulation by compounds","volume":"57","author":"Peri","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.intimp.2026.116884_bb0170","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3390\/vaccines5040034","article-title":"TLR4 pathway modulators","volume":"5","author":"Kuzmich","year":"2017","journal-title":"Vaccines"},{"key":"10.1016\/j.intimp.2026.116884_bb0175","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.3389\/fimmu.2020.01210","article-title":"Small-molecule TLR4 modulators","volume":"11","author":"Romerio","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116884_bb0180","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/bcp.13216","article-title":"The drugs that mostly frequently induce acute kidney injury: a case - noncase study of a pharmacovigilance database","volume":"83","author":"Pierson-Marchandise","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.intimp.2026.116884_bb0185","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.1007\/s00330-023-10420-w","article-title":"Long-term cardiotoxicity of platinum therapy","volume":"34","author":"Beitzen-Heineke","year":"2024","journal-title":"Eur. Radiol."},{"key":"10.1016\/j.intimp.2026.116884_bb0190","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.847012","article-title":"Cardiotoxicity of anticancer drugs","volume":"9","author":"Morelli","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.intimp.2026.116884_bb0195","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.7150\/thno.69424","article-title":"Platinum-based anticancer drugs","volume":"12","author":"Zhang","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.intimp.2026.116884_bb0200","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s10157-024-02490-x","article-title":"Integrated view of cisplatin toxicity","volume":"28","author":"Oliveira","year":"2024","journal-title":"Clin. Exp. Nephrol."},{"key":"10.1016\/j.intimp.2026.116884_bb0205","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1161\/HYPERTENSIONAHA.119.13022","article-title":"TLR4 antagonism prevents LV hypertrophy","volume":"74","author":"Mian","year":"2019","journal-title":"Hypertension"},{"key":"10.1016\/j.intimp.2026.116884_bb0210","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/j.1440-1681.2008.05121.x","article-title":"TAK-242 prevents endotoxaemia","volume":"36","author":"Kuno","year":"2009","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.intimp.2026.116884_bb0215","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1093\/eurjhf\/hfr035","article-title":"TLR4 antagonist eritoran and hypertrophy","volume":"13","author":"Ehrentraut","year":"2011","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.intimp.2026.116884_bb0220","article-title":"ApTOLL in myocardial infarction","volume":"10","author":"Ramirez-Carracedo","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.intimp.2026.116884_bb0225","first-page":"I270","article-title":"Eritoran and myocardial I\/R injury","volume":"114","author":"Shimamoto","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.intimp.2026.116884_bb0230","doi-asserted-by":"crossref","first-page":"5649","DOI":"10.1007\/s00210-024-02956-5","article-title":"Edaravone and obeticholic acid protect against cisplatin-induced heart toxicity by suppressing oxidative stress and inflammation and modulating Nrf2, TLR4\/p38MAPK, and JAK1\/STAT3\/NF-\u03baB signals","volume":"397","author":"El-Shoura","year":"2024","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.intimp.2026.116884_bb0235","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.yjmcc.2015.11.002","article-title":"Inflammatory responses of cardiac fibroblasts","volume":"94","author":"Turner","year":"2016","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.intimp.2026.116884_bb0240","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10840-022-01209-w","article-title":"Circ-TLR4 and cardiac hypertrophy","volume":"65","author":"Li","year":"2022","journal-title":"J. Interv. Card. Electrophysiol."},{"key":"10.1016\/j.intimp.2026.116884_bb0245","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1510477","article-title":"Hypoalbuminemia and cisplatin-induced acute kidney injury","volume":"15","author":"Yin","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2026.116884_bb0250","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1103062","article-title":"Autophagy and necroptosis in cisplatin acute kidney injur","volume":"14","author":"Alassaf","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2026.116884_bb0255","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1155\/MI.2005.139","article-title":"Lipid peroxides in cisplatin nephrotoxicity","author":"Gonz\u00e1lez","year":"2005","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.intimp.2026.116884_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.108053","article-title":"Targeting NLRP3 inflammasome in CVD","volume":"236","author":"Toldo","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2026.116884_bb0265","first-page":"488","article-title":"Renal effects of TLR4 inhibition in sepsis","volume":"18","author":"Fenhammar","year":"2014","journal-title":"Crit. Care"},{"key":"10.1016\/j.intimp.2026.116884_bb0270","article-title":"TAK-242 in septic AKI","volume":"46","author":"Xia","year":"2024","journal-title":"Ren. Fail."},{"key":"10.1016\/j.intimp.2026.116884_bb0275","article-title":"TAK-242 protects cardiac and renal injury","volume":"10","author":"Zhang","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.intimp.2026.116884_bb0280","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s40620-020-00722-3","article-title":"TLR4\/MyD88\/NF-\u03baB in IgA nephropathy","volume":"33","author":"Zhang","year":"2020","journal-title":"J. Nephrol."},{"key":"10.1016\/j.intimp.2026.116884_bb0285","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.714340","article-title":"NLRP3 inflammasome in metabolic kidney diseases","volume":"12","author":"Xiong","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116884_bb0290","article-title":"Salvianolic acid B and TLR4\/NLRP3 inhibition","volume":"2022","author":"Pei","year":"2022","journal-title":"Evid. Based Complement. Alternat. Med."},{"key":"10.1016\/j.intimp.2026.116884_bb0295","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0003596","article-title":"Toll-like receptor-4 coordinates the innate immune response of the kidney to renal ischemia\/reperfusion injury","volume":"3","author":"Pulskens","year":"2008","journal-title":"PloS One"},{"key":"10.1016\/j.intimp.2026.116884_bb0300","article-title":"TLR2\/4 and inflammasome in nephritis","volume":"6","author":"Correa-Costa","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.intimp.2026.116884_bb0305","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jep.2015.04.011","article-title":"Wuling San protects kidney function via TLR4\/NLRP3 inhibition","volume":"169","author":"Yang","year":"2015","journal-title":"J. Ethnopharmacol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926007307?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926007307?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T22:30:21Z","timestamp":1783117821000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926007307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":61,"alternative-id":["S1567576926007307"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116884","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TLR4 receptor blockade diminishes cardiac and renal toxicity induced by cisplatin treatment in rats","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116884","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"116884"}}